Aquestive Therapeutics (AQST) Enterprise Value (2018 - 2026)

Aquestive Therapeutics has reported Enterprise Value for 9 years, with the latest figure at $423.6 million in Q2 2026.

• On a quarterly basis, Enterprise Value rose 57.88% year-over-year to $423.6 million in Q2 2026; TTM through Jun 2026 was $423.6 million, a 57.88% increase from a year earlier, with the FY2025 full-year figure at $667.2 million, up 162.81% from the prior year.
• Enterprise Value was $423.6 million for Q2 2026 at Aquestive Therapeutics, up from $405.0 million in the prior quarter.
• The five-year high for Enterprise Value was $667.2 million in Q4 2025, with the low at $16.4 million in Q2 2022.
• Average Enterprise Value over 5 years is $223.0 million, with a median of $182.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value tumbled 86.18% in 2022, then surged 492.36% in 2024.
• Over 5 years, Enterprise Value stood at $22.2 million in 2022, then surged by 416.36% to $114.6 million in 2023, then surged by 121.61% to $253.9 million in 2024, then surged by 162.81% to $667.2 million in 2025, then sank by 36.51% to $423.6 million in 2026.
• The last three Enterprise Value figures came in at $423.6 million (Q2 2026), $405.0 million (Q1 2026), and $667.2 million (Q4 2025), per Business Quant data.